Botulinum Toxin A in Clinical Practice, the Technical Aspects and What Urologists Want to Know about It

被引:4
|
作者
van Breda, Hendrikje M. K. [1 ]
Heesakkers, John P. F. A. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6500 HB Nijmegen, Netherlands
关键词
Botulinum toxin; Neurogenic detrusor overactivity; OnabotulinumtoxinA; Overactive bladder; Urinary incontinence; NEUROGENIC DETRUSOR OVERACTIVITY; PLACEBO-CONTROLLED TRIAL; URINARY-INCONTINENCE; DOUBLE-BLIND; BLADDER; ONABOTULINUMTOXINA; INJECTIONS; EXPERIENCE; EFFICACY; IMPROVES;
D O I
10.1159/000381881
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To give an overview of the literature concerning the clinical practice of Botulinum toxin A (BTA) treatment to meet the needs and knowledge of urologists. Methods: A literature search was performed to BTA treatment, together with a survey among Dutch urologist. Results: The registration trials used strict inclusion and exclusion criteria, a standardized application technique and follow-up. The approval for BTA is based on these trials but differs from country to country. BTA was already used before these approvals, with different application techniques. Published manuscripts about application techniques (trigone sparing/suburothelial injections/intradetrusor injections) show different outcomes. In literature there is no positive or negative predictor found with a preoperatively urodynamic investigation. It is shown that retreatment does not cause inflammatory infiltration or fibrosis in the bladder wall. The survey showed that in 96% of the urology departments BTA is used. Urodynamic investigation is requested by 87% of urologists before the treatment. Although it is regarded as an easy-to-learn procedure 60% of urologists would like training in practical aspects. Conclusions: No firm data exist about the technique of application with consequently the most optimal results. BTA treatment is regarded as an easy-to-learn, but still there is a request for training in practical treatment aspects. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:411 / 416
页数:6
相关论文
共 39 条
  • [1] Intravesical botulinum toxin: Practice patterns from a survey of Canadian urologists
    Ross, James
    Hickling, Duane
    Maciejewski, Conrad
    Coriaty, Rhea
    Vigil, Humberto
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2023, 17 (01): : E15 - E22
  • [2] Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva, Carlos Martins
    Cruz, Francisco
    CURRENT OPINION IN UROLOGY, 2009, 19 (04) : 347 - 352
  • [3] Use of Botulinum Toxin in Orofacial Clinical Practice
    Serrera-Figallo, Maria-Angeles
    Ruiz-de-Leon-Hernandez, Gonzalo
    Torres-Lagares, Daniel
    Castro-Araya, Alejandra
    Torres-Ferrerosa, Omar
    Hernandez-Pacheco, Esther
    Gutierrez-Perez, Jose-Luis
    TOXINS, 2020, 12 (02)
  • [4] Botulinum toxin for chronic migraine: Clinical trials and technical aspects
    Tassorelli, Cristina
    Sances, Grazia
    Avenali, Micol
    De Icco, Roberto
    Martinelli, Daniele
    Bitetto, Vito
    Nappi, Giuseppe
    Sandrini, Giorgio
    TOXICON, 2018, 147 : 111 - 115
  • [5] What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection
    Khan, Shahid
    Kessler, Thomas M.
    Apostolidis, Apostolos
    Kalsi, Vinay
    Panicker, Jalesh
    Roosen, Alexander
    Gonzales, Gwen
    Haslam, Collete
    Elneil, Sohier
    Fowler, Clare J.
    Dasgupta, Prokar
    JOURNAL OF UROLOGY, 2009, 181 (04) : 1773 - 1778
  • [6] Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity
    Perrouin-Verbe, B.
    Ruffion, A.
    Game, X.
    Denys, P.
    Kerdraon, J.
    Karsenty, G.
    de Seze, M.
    Haab, F.
    Saussine, C.
    Soler, J. -M.
    Amarenco, G.
    Chartier-Kastler, E.
    PROGRES EN UROLOGIE, 2009, 19 (06): : 372 - 382
  • [7] Clinical Practice: evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin
    Contarino, Maria Fiorella
    Van den Dool, Joost
    Balash, Yacov
    Bhatia, Kailash
    Giladi, Nir
    Koelman, Johannes H.
    Lokkegaard, Annemette
    Marti, Maria J.
    Postma, Miranda
    Relja, Maja
    Skorvanek, Matej
    Speelman, Johannes D.
    Zoons, Evelien
    Ferreira, Joaquim J.
    Vidailhet, Marie
    Albanese, Alberto
    Tijssen, Marina A. J.
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [8] Multiple sclerosis (MS) for the urologist: What should urologists know about MS?
    Aharony, Shachar
    Lam, Ornella
    Lapierre, Yves
    Corcos, Jacques
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 (02) : 174 - 179
  • [9] Clinical practice guidelines for the treatment of spasticity with botulinum toxin
    Garreta-Figuera, Roser
    Chaler-Vilaseca, Joaquim
    Torrequebrada-Gimenez, Agustin
    REVISTA DE NEUROLOGIA, 2010, 50 (11) : 685 - 699
  • [10] Botulinum Toxin Therapy for Psychiatric Disorders in Clinical Practice: A Retrospective Case Study
    Lehnert, Franziska
    Neumann, Insa
    Krueger, Tillmann H. C.
    Wollmer, Marc A.
    TOXINS, 2023, 15 (06)